High-dose pegylated interferon-α and ribavirin in nonresponder hepatitis C patients and relationship with IL-28B genotype (SYREN Trial)

Gastroenterology

Volumn 141, Issue 1, 2011, Pages 119-127

  Chevaliez, Stéphane ^a,b   Hézode, Christophe ^a   Soulier, Alexandre ^a,b   Costes, Bruno ^a,b   Bouvieralias, Magali ^a,b   Rouanet, Stéphanie ^c   Foucher, Juliette ^d   Bronowicki, Jeanpierre ^e   Tran, Albert ^f   Rosa, Isabelle ^g   Mathurin, Philippe ^h   Alric, Laurent ⁱ   Leroy, Vincent ^j   Couzigou, Patrice ^d   Mallat, Ariane ^a,b   Charafeddine, Mariem ^c   Babany, Gérard ^c   Pawlotsky, Jeanmichel ^a,b  

^a HENRI MONDOR HOSPITAL   (France)

^b INSERM U955   (France)

^c Roche   (France)

^d HAUT LÉVÊQUE HOSPITAL   (France)

^e INSERM   (France)

^f CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

^g CENTRE HOSPITALIER INTERCOMMUNAL DE CRÉTEIL   (France)

^h UNIV LILLE   (France)

ⁱ UNIVERSITÉ DE TOULOUSE   (France)

^j UNIV GRENOBLE ALPES   (France)

more..

Author keywords

Hepatitis C Virus; High Dose Pegylated IFN ; IL 28B Genotype; Nonresponder

Indexed keywords

INTERLEUKIN 28B; PEGINTERFERON ALPHA2B; RIBAVIRIN; VIRUS RNA;

ADULT; ALOPECIA; ANEMIA; ANOREXIA; ANTIVIRAL THERAPY; APPETITE; ARTICLE; ASTHENIA; BACKACHE; CONTROLLED STUDY; COUGHING; DEPRESSION; DIARRHEA; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG RESPONSE; DYSPNEA; ECZEMA; FEMALE; FLU LIKE SYNDROME; GENOTYPE; HEPATITIS C; HUMAN; INSOMNIA; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MYALGIA; NAUSEA; NEUTROPENIA; OPEN STUDY; PATIENT MONITORING; PREDICTION; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RNA ANALYSIS; SIDE EFFECT; SINGLE NUCLEOTIDE POLYMORPHISM; SLEEP DISORDER; THROMBOCYTOPENIA; TREATMENT RESPONSE; VIROLOGY;

EID: 79959940465     PISSN: 00165085     EISSN: 15280012     Source Type: Journal    
DOI: 10.1053/j.gastro.2011.03.039     Document Type: Article

References (28)

1. Global Burden of Hepatitis C Working Group Global burden of disease (GBD) for hepatitis C J Clin Pharmacol 44 2004 20 29
2. J.F. Perz, G.L. Armstrong, and L.A. Farrington The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide J Hepatol 45 2006 529 538 (Pubitemid 44307383)
3. M.W. Fried, M.L. Shiffman, and K.R. Reddy Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection N Engl J Med 347 2002 975 982
4. S.J. Hadziyannis, H. Sette Jr, and T.R. Morgan Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose Ann Intern Med 140 2004 346 355
5. M.P. Manns, J.G. McHutchison, and S.C. Gordon Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial Lancet 358 2001 958 965 (Pubitemid 32913521)
6. D. Ge, J. Fellay, A.J. Thompson, and J.S. Simon Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance Nature 461 2009 399 401
7. V. Suppiah, M. Moldovan, and G. Ahlenstiel IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy Nat Genet 41 2009 1100 1104
8. Y. Tanaka, N. Nishida, and M. Sugiyama Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C Nat Genet 41 2009 1105 1109
9. C. Hezode, N. Forestier, and G. Dusheiko Telaprevir and peginterferon with or without ribavirin for chronic HCV infection N Engl J Med 360 2009 1839 1850
10. P.Y. Kwo, E.J. Lawitz, and J. McCone Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial Lancet 376 2010 705 716
11. J.G. McHutchison, G.T. Everson, and S.C. Gordon Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection N Engl J Med 360 2009 1827 1838
12. J.G. McHutchison, M.P. Manns, and A.J. Muir Telaprevir for previously treated chronic HCV infection N Engl J Med 362 2010 1292 1303
13. T. Berg, J.G. McHutchison, and N. Adda SVR with telaprevir, peginterferon alfa-2a and ribavirin in HCV patients with well-characterized prior null-response, partial response, viral breakthrough or relapse after PR J Hepatol 52 Suppl 1 2010 S2
14. I.M. Jacobson, J.G. McHutchison, and G.M. Dusheiko Telaprevir in combination with peginterferon and ribavirin in genotype 1 HCV treatment-naive patients: final results of Phase 3 ADVANCE study Hepatology 52 Suppl 2010 427A
15. B.R. Bacon, S.C. Gordon, and E. Lawitz HCV RESPOND-2 final results: high sustained virologic response among genotype 1 previous nonresponders and relapsers to peginterferon/ribavirin when retreated with boceprevir plus PegIntron (peginterferon alfa-2b)/ribavirin Hepatology 52 Suppl 2010 430A
16. F. Poordad, J. McCone, and B.R. Bacon Boceprevir (BOC) combined with peginterferon alfa-2b/ribavirin (P/R) for treatment-naive patients with hepatitis C virus (HCV) genotype 1: SPRINT-2 final results Hepatology 52 Suppl 2010 402A
17. K.E. Sherman, S.L. Flamm, and N.H. Afdhal Telaprevir in combination with peginterferon alfa2a and ribavirin for 24 or 48 weeks in treatment-naive genotype 1 HCV patients who achieved an extended rapid viral response: final results of Phase 3 ILLUMINATE study Hepatology 52 Suppl 2010 401A
18. J.M. Pawlotsky Treatment failure and resistance with direct acting antiviral drugs against hepatitis C virus Hepatology 53 2011 1742 1751
19. A. Rauch, Z. Kutalik, and P. Descombes Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study Gastroenterology 138 2010 1338 1345
20. J.J. McCarthy, J.H. Li, and A. Thompson Replicated association between an IL28B gene variant and a sustained response to pegylated interferon and ribavirin Gastroenterology 138 2010 2307 2314
21. S. Chevaliez, M. Bouvier-Alias, and R. Brillet Overestimation and underestimation of hepatitis C virus RNA levels in a widely used real-time polymerase chain reaction-based method Hepatology 46 2007 22 31 (Pubitemid 47171917)
22. M.G. Swain, M.Y. Lai, and M.L. Shiffman A sustained virologic response is durable in patients with chronic hepatitis C treated with peginterferon alfa-2a and ribavirin Gastroenterology 139 2010 1593 1601
23. F.E. Lotrich, J.M. Loftis, and R.E. Ferrell IL28B polymorphism is associated with both side effects and clearance of hepatitis C during interferon-alpha therapy J Interferon Cytokine Res 2010 Dec 6 [Epub ahead of print]
24. D.M. Jensen, P. Marcellin, and B. Freilich Re-treatment of patients with chronic hepatitis C who do not respond to peginterferon-alpha2b: a randomized trial Ann Intern Med 150 2009 528 540
25. T. Poynard, M. Colombo, and J. Bruix Peginterferon alfa-2b and ribavirin: effective in patients with hepatitis C who failed interferon alfa/ribavirin therapy Gastroenterology 136 2009 1618 1628 e2
26. M.L. Shiffman, A.M. Di Bisceglie, and K.L. Lindsay Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment Gastroenterology 126 2004 1015 1023 (Pubitemid 38451173)
27. G. Taliani, G. Gemignani, and C. Ferrari Pegylated interferon alfa-2b plus ribavirin in the retreatment of interferon-ribavirin nonresponder patients Gastroenterology 130 2006 1098 1106
28. A. Neumann, S. Bibert, and B. Haagmans IL28B polymorphism is significantly correlated with IFN antiviral effectiveness already on first day of pegylated interferon alpha and ribavirin therapy of chronic HCV infection J Hepatol 52 Suppl 1 2010 S468